News

Brian T. Hill, MD, PhD, reflects on how the approval of CAR T-cell therapy has impacted clinical practice for his patients with MCL, ongoing research with practice-changing implications, and how MCL treatment has evolved during the coronavirus disease 2019 pandemic.

Intravitreal gene therapy continues to be well tolerated and shows robust efficacy

Brian T. Hill, MD, PhD, discusses the advent of CAR T-cell therapies, such as axicabtagene ciloleucel, tisagenlecleucel, and brexucabtagene autoleucel, and how they have shifted lymphoma treatment into a new era.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for KTE-X19 as a treatment in adult patients with relapsed/refractory mantle cell lymphoma who previously received 2 or more lines of systemic therapy, including a BTK inhibitor.

Targeted therapy and immunotherapy have improved survival outcomes for patients with metastatic renal cell carcinoma.

New data showing efficacy and tolerability with ADP-A2AFP, alpha-fetoprotein–directed specific peptide enhanced affinity receptor T-cells, suggest that further research evaluating the 5 billion or more cell dosing regimen is warranted in hepatocellular carcinoma.

Patients treated with Axovant’s gene therapy AXO-Lenti-PD reported improvements of 40% in UPDRS-III scores, and 71% improvement in activities of daily living.

The process of approving a new therapy for relapsing and/or remitting mantle cell lymphoma therapy got off to a faster start in China, but United States regulators caught up and approved the drug first.

Researchers identified molecular and cellular characteristics of anti-CD19 CAR T-cell infusion products associated with how patients with large B-cell lymphoma respond to treatment and experience adverse events.

The investigational advanced cell therapy omidubicel resulted in rapid platelet engraftment and reduced the number of infections and hospitalizations in patients with high-risk hematologic malignancies, meeting all 3 secondary end points of a phase 3 trial.

The FDA has granted a breakthrough therapy designation to IMGN632 for the treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm.

The FDA granted breakthrough therapy designation to IMGN632 for the treatment of patients with relapsed or refractory blastic plasymacytoid dendritic cell neoplasm.

Solid Biosciences noted that its response to the agency requests for further information about manufacturing as well as updated safety and efficacy data on all dosed patients led to the lift.

The FDA granted fast track designation to the novel “switchable” CAR-T cell therapy known as CLBR001 + SWI019 for the treatment of B-cell malignancies.

Kami Maddocks, MD, discusses the significance of the selinexor approval in the diffuse large B-cell lymphoma treatment paradigm, emerging strategies that seek to address unmet needs, and remaining sequencing questions.

The complexities associated with the disease and lack of validated risk predictors makes such a model challenging to implement.

David H. Vesole, MD, PhD, discusses the evolution of multiple myeloma treatment, and explained how other BCMA-therapies are poised to impact clinical practice.

Results from the phase 1/2 ALEXANDER study found the investigational CAR T-cell product AUTO3 in combination with pembrolizumab to have a tolerable safety profile and elicit durable complete responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

Efforts to leverage targeted therapy and immunotherapy, which have been approved modalities in advanced non–small cell lung cancer, are leading to improved survival in patients with advanced and earlier-stage disease.

A year after the FDA approved Zolgensma for the treatment of spinal muscular atrophy in children aged under 2 years without end-stage weakness, researchers shared safety and early efficacy data from the first 21 children treated with the gene therapy in Ohio.

Investigators find that nanoparticles deliver gene therapy successfully in mice, rats.

Investigators find that nanoparticles deliver gene therapy successfully in mice, rats.

The investigational CAR T-cell product AUTO3 in combination with pembrolizumab was found to have a tolerable safety profile and elicit durable complete responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

Findings from the noncomparative, phase 2, biomarker-driven BIONIKK trial support the use of molecularly-directed frontline therapy as means to enrich responses in patients with metastatic clear cell renal cell carcinoma.

FDA will review the first chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of multiple myeloma (MM) in adults who have not responded or have relapsed after at least 3 other therapies.

The comprehensive cancer center has also dosed its first patient in chlorotoxin CAR T cell therapy trial.

Findings from the noncomparative, phase 2, biomarker-driven BIONIKK trial demonstrated clinical evidence to support the use of molecularly-directed frontline therapy as means to enrich responses in patients with metastatic clear cell renal cell carcinoma.

Cemiplimab-rwlc monotherapy led to a significant improvement in overall survival and progression-free survival versus platinum-doublet chemotherapy as first-line therapy in patients with advanced non–small cell lung cancer with PD-L1 expression on at least 50% of their tumor cell.

Atara Biotherapeutics’ allogeneic EBV-targeted T-cell therapy, ATA188, is well-tolerated in phase 1, with a dose identified for the randomized placebo-controlled portion of the study.

BLU-945, an investigational precision therapy, elicited robust antitumor activity in multiple preclinical models of triple-mutated EGFR-positive non–small cell lung cancer .